Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17086808 | 0.83 | ADRA2A (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL15255357 | 0.83 | ADRA2A (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL19670036 | 0.83 | ADRA2A (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL10024963 | 0.83 | ADRA2A (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL29999110 | 0.83 | DPP4 (0.52) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL25392684 | 0.83 | ADRA2A (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL3955929 | 0.83 | ADRA2A (0.58) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL908216 | 0.82 | TAAR1 (0.50) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL10024960 | 0.81 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL21588545 | 0.81 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077444-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT, BRANCHED, ACYCLIC POLYALKYLENEAMINES AND MIXTURES THEREOF | Dow Global Technologies LLC (US) | 2016-10-12 | — | — | EP | claimed |
| WO-2015084619-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT, BRANCHED, ACYCLIC POLYALKYLENEAMINES AND MIXTURES THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-11 | — | — | WO | claimed |
| EP-3310830-A1 | AUTOCATALYTIC POLYOL USEFUL FOR POLYURETHANE FOAM MANUFACTURE | Dow Global Technologies LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016204981-A1 | AUTOCATALYTIC POLYOL USEFUL FOR POLYURETHANE FOAM MANUFACTURE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-22 | — | — | WO | disclosed |
| EP-3077444-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT, BRANCHED, ACYCLIC POLYALKYLENEAMINES AND MIXTURES THEREOF | Dow Global Technologies LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015084619-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT, BRANCHED, ACYCLIC POLYALKYLENEAMINES AND MIXTURES THEREOF | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-2638003-A1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO HIGH MOLECULAR WEIGHT POLYALKYLENEAMINES | Dow Global Technologies LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064484-A1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO HIGH MOLECULAR WEIGHT POLYALKYLENEAMINES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| US-6803484-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20040143020-A1 | Sulfonamide derivatives | AIKINS JAMES ABRAHAM (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6300501-B1 | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase | WARNER-LAMBERT COMPANY | 2001-10-09 | — | — | US | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0938494-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1997044350-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0384774-B1 | Semiconductor device encapsulant | TOSHIBA KK (JP) | 1997-01-22 | — | — | EP | disclosed |
| US-5258426-A | Semiconductor device encapsulant | KABUSHIKI KAISHA TOSHIBA (JP) | 1993-11-02 | — | — | US | disclosed |
| EP-0384774-A2 | Semiconductor device encapsulant | KABUSHIKI KAISHA TOSHIBA (JP) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143020-A1 | Sulfonamide derivatives | GRIN2A, GRIN2B, SLC1A2 | DPP4 2993/4885F2 3179/4885ADRA2A 1259/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | DPP4 226/4885F2 3117/4885ADRA2A 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.